GlomCon's Clinical Trial Portal
A platform to help HOPE
find OPPORTUNITY
.png)
Featured Clinical Trials
Atypical Hemolytic Uremic Syndrome
Study Sponsor: Novartis Pharmaceuticals
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS).
IC-MPGN
Study Sponsor: Novartis Pharmaceuticals
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN (APPARENT).
Lupus Nephritis
Study Sponsor: Novartis Pharmaceuticals
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Lupus Nephritis
Study Sponsor: Novartis Pharmaceuticals
A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)
C3 Glomerulopathy
Study Sponsor: Novartis Pharmaceuticals
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. (APPEAR-C3G).
IgA Nephropathy
Study Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
APOL-1 Mediated Kidney Disease
Study Sponsor: Vertex Pharmaceuticals Incorporated
Phase 2/​3 Adaptive Study of VX-147 in Adults With APOL1-mediated Proteinuric Kidney Disease
Lupus Nephritis
Study Sponsor: Novartis Pharmaceuticals
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
GlomCon's Corporate Supporters
We gratefully acknowledge the support and partnership of corporations dedicated to improving the lives of patients with glomerular diseases.
​
The support from our corporate members and our strategic partners allows us to come up with bold ideas and helps us pursue our mission.
Contact Us
Questions? Concerns? Reach out to GlomCon's Clinical Trials team at support@glomcon.org